ArticleInfectious diseases of poverty2026
Antibody landscapes of arboviral exposure across China revealed by high-throughput seroprofiling from a peptide epitope library.
Article in Infectious diseases of poverty, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundArboviral infections impose significant public health challenges globally, yet routine surveillance typically captures only symptomatic infections, underestimating the true extent of exposure. Insights into how regional and demographic factors influence population immunity are essential for targeted surveillance and prevention, but such multidimensional insights remain limited. This study aimed to quantify population-level arboviral sero exposure and delineate the effects of regional and demographic factors on immunity to inform targeted surveillance and prevention.
methodsWe utilized a programmable phage display platform, ArboScan, which evaluates antibody binding to overlapping peptides that represent the proteomes of 691 human and zoonotic arboviruses. We profiled baseline antibody reactivity in serum samples from 400 healthy individuals, collected before the dengue outbreaks reported in Hainan in 2019. Antibody reactivity was quantified as normalized fold-change (FC) values relative to negative controls, and analyzed by region, sex, and age. Normality was assessed using the Shapiro-Wilk test. Two-group comparisons were conducted using independent two-sample t tests for normally distributed data or Mann-Whitney U tests otherwise; comparisons among > 2 groups were performed using One-way Analysis of Variance for normally distributed data.
resultsRegional ranking by mean product fold change (MPFC) showed northern enrichment for bluetongue virus (MPFC = 3.56), whereas southern cohorts were enriched for mosquito-borne arboviruses-dengue virus (MPFC = 3.54), Alagoas vesiculovirus (MPFC = 3.50), and Venezuelan equine encephalitis virus (MPFC = 3.39). Females exhibited higher FC than males for selected arboviral families (P < 0.001). By family-level analysis, Flaviviridae, Togaviridae, and Phenuiviridae showed no age-stratified differences (P > 0.05). High fold-change values were detected for non-arboviral viruses such as human cytomegaloviruses and human adenoviruses across all regions.
conclusionsOur findings reveal distinct regional and demographic patterns of arboviral antibody reactivity in China, reflecting differing histories of exposure and potentially informing region-specific surveillance strategies. The stable antibody levels across age groups, together with higher fold-change values in females, underscore the influence of biological and social factors on arboviral immunity. The ArboScan platform, and programmable peptide display platforms in general, offer a scalable approach to characterize population-level immunity and could enhance early detection and public health preparedness in arbovirus-endemic areas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.